Eric Sagonowsky

1 week ago | fiercepharma.com | Eric Sagonowsky

After exploring a rival buyout offer worth 50% more than its first, bluebird bio is back where it started. Wednesday, the company said that it's sticking with the decision to sell to private equity firms Carlyle and SK Capital for $3 per share, plus a contingent payment of $6.84 per share if it meets a future net sales threshold.

3 weeks ago | fiercepharma.com | Eric Sagonowsky |Fraiser Kansteiner

Amid a dramatic reshaping of the federal healthcare apparatus, the FDA has named an acting leader of its Center for Biologics Evaluation and Research. Agency adviser Scott Steele, Ph.D., will take over the key center for the time being, the FDA said on a post on X late Monday. Steele has been a full-time adviser to CBER since late 2022, according to his LinkedIn profile. Before that, he advised the FDA's Office of Medical Policy Initiatives from June 2020 to September 2022.

3 weeks ago | fiercepharma.com | Eric Sagonowsky

It's not yet been a week since Marty Makary, M.D., was confirmed to lead the FDA as its commissioner. But he's already played a behind-the-scenes role in a controversial decision that has put some in the biopharma industry at odds with the Trump administration. That's according to reporting from Politico, which details the deliberations that led to the departure of Peter Marks, M.D., Ph.D., the former leader of the agency's Center for Biologics Evaluation and Research (CBER).

1 month ago | fiercepharma.com | Andrea Park |Eric Sagonowsky |Angus Liu

Johnson & Johnson’s Stelara, Regeneron’s Eylea and Amgen’s Prolia are just some of the drugs facing off against new biosimilars or generics in 2025, as featured in the latest edition of Fierce Pharma’s annual special report documenting the 10 biggest losses of U.S. exclusivity expected throughout the year.

1 month ago | fiercepharma.com | Eric Sagonowsky |Andrea Park |Kevin Dunleavy |Angus Liu

Diseases: Osteoporosis at high risk of fracture, bone loss in patients with prostate or breast cancer undergoing hormone ablation therapy; prevention of skeletal-related events in patients with bone metastases from cancer, giant cell tumor of the bone, hypercalcemia of malignancyCompany: Amgen2024 U.S. sales: $4.39 billionAmgen’s Prolia and Xgeva, which share the same active ingredient denosumab, have had a good run.